Explaining ASX Healthcare Shares: Biotechnology To Medical Equipment and Why It Matters To Investors

The healthcare sector has spent much of 2026 going against the expectations associated with it. Healthcare is meant to be the defensive part of the market where investors shelter themselves when all hell breaks loose elsewhere. But it was responsible for some of the largest one-day losses seen by individual stocks on the ASX this year, with Cochlear losing 40.7% in a single day in April, which was its worst ever loss, following cut-down profit forecasts. CSL is off roughly 43% this year and nearly 60% from last year at current levels, hitting its lowest level in ten years. Meanwhile, ResMed also suffered a loss but made some gains back since then. This is a strange year for a sector based on the premise of reliable, recession-proof demand.

The healthcare space is not a monolith

 To put all the healthcare stocks in one basket renders the classification meaningless. There are at least four distinctly different industries sitting behind the same label and responding to different forces.

Firstly, biotechnology businesses such as CSL produce biological products for instance, plasma-derived products through the Behring division, accounting for about 60% of group revenue. Such businesses operate on the R&D model, tend to be globally oriented and vulnerable to timing of regulatory approvals and pricing in the largest market, the US.

Secondly, medical devices manufacturers like Cochlear and ResMed are producers of tangible products – Cochlear implants for the former, sleep apnoea devices and masks for the latter. In addition, the split between one-off device sales and revenues from recurrent consumables becomes relevant in the latter's case – ResMed's masks and accessories account for 35% of revenue and resemble subscription-based income, thus providing an additional layer of safety compared to device-only businesses.

Thirdly, diagnostic and hospital operators like Sonic Healthcare and Ramsay Health Care provide services, not tangible products — pathology testing, imaging and surgical services. In this industry, demand follows the population's health needs and less likely to be driven by the economic cycle, hence explaining high routine testing volumes even during periods of reduced consumer spending.

Health tech constitutes a smaller and newer industry, represented only by Pro Medicus. This is the most unusual business model among those considered – Pro Medicus does not manufacture any physical products, it creates a Visage platform that hospitals and radiology service providers use to store and process diagnostic scans. For the FY26 H1, Pro Medicus generated 28% revenue growth to roughly $125 million, with EBIT margins above 70% and debt-free balance sheet with over $220 million of net cash. Obviously, this represents a very different risk structure compared to plasma or device producers with manufacturing facilities and supply chains.
Finally, there is radiopharmaceuticals. Telix Pharmaceuticals produces targeted radiation products used to diagnose and treat cancers and became the leading name in this field on the ASX, guided to US$950–970 million of revenue in 2026 driven by its prostate cancer imaging product Illuccix.

The factors which have dented the sector

The 2026 sell-off has not been due to one factor but a combination of them coming in rapid succession. The fall in CSL has occurred because of the pricing pressure on plasma in its key Behring business and the various earnings downgrades, the latest of which saw forecasts being reduced to around US$15.2 billion (constant currency) after a 90-day strategic review led by interim CEO Gordon Naylor. In addition, analysts have highlighted that the impact of the anti-vaccine sentiments in the US has affected some elements of the business.

The fall of Cochlear, however, has been sudden and resulted in a guidance cut, which saw 40% shaved off the share price. This in turn took down the whole sector, as CSL fell 5.7%, and ResMed 2.5%, purely for sympathy reasons. The fall in ResMed, however, has been different once again, and is because of fears about the GLP-1 drugs for weight loss reducing the number of patients who need treatment with CPAP machines, something which ResMed itself has disagreed with, arguing the use of GLP-1 drugs increases diagnosis rate instead.
The wider trend that affects all three stocks is the factor of sector rotation. The capital that flowed from the healthcare sector to energy and resource sector has taken down the whole sector once a major player like Cochlear has issued guidance cut and the market expects weaker consumer spending to affect other premium healthcare names.

 Some early signs of the turnaround, albeit with caution

The segment has managed to partially make up for the losses. The S&P/ASX 200 Healthcare index gained 17-21% between early June and early July, breaking above its 50-day moving average for the first time since August 2025. It was Pro Medicus, Telix, and recovering CSL who fueled this rally. However, the analysts who cover the sector have been cautiously upbeat about the bottom in rather than jumping to celebrate it — Macquarie, for example, held a Neutral view on both CSL and Cochlear throughout the rally, boosting target prices only slightly and noting that the earnings' recovery to warrant further re-rating has yet to materialize. Both CSL and Cochlear remain considerably below their 200-day moving averages despite the rally, and UBS forecast suggests that the size of CSL's drop in the stock price far exceeds its earnings decline — the firm expects the company's EPS to rise by about 2% in FY27, while in the past year the stock has fallen by 53%.

 Implications for interpreting the sector

The situation in 2026 serves as a helpful reminder about the difference between "defensive" and "safe". True, the healthcare demand is inelastic, however, balance sheets, product pipelines, and price exposures are far from being so. Hence, a bad earnings guidance from one company might negatively impact sentiment in names which do not share the problems it is facing. The companies in this sector operate on quite different fundamentals – a software company like Pro Medicus without a factory and strong margins simply shares nothing, economically speaking, with a plasma manufacturer trying to navigate its way around the US pricing policy and a medical device company exposed to a single product cycle coming soon.

The only thing tying these five different categories into one is an ongoing demographic trend which will lead to nearly doubling Australia's population aged over 65 years by 2060. Chronic diseases' prevalence continues to fuel demand in diagnostics, pharmaceuticals, and hospital services no matter how good/bad the stocks' performance is in their particular cycles at the moment.

( Source : Market Analysis )